France· FR:64103073
FLUTICASONE FUROATE SUBSTIPHARM 27,5 microgrammes/pulvérisation, suspension pour pulvérisation nasale
A medicinal product containing furoate de fluticasone, registered in France by SUBSTIPHARM, on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- FUROATE DE FLUTICASONE
- Manufacturer
- SUBSTIPHARM
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009302995861 flacon en verre brun de 15 mL (120 pulvérisations) avec pompe doseuse avec embout nasal polypropylèneEUR 3.88
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Furoate de fluticasone in 17 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United States24 Hour Allergy NasalWalgreen Company
- United KingdomAvamys 27.5micrograms/dose nasal sprayMawdsley-Brooks & Company Ltd
- FinlandAvamysGlaxoSmithKline (Ireland) Limited
- SpainAVAMYS 27,5 mcg/PULVERIZACION PARA SUSPENSION NASALGlaxo Group Limited
- BelgiumAerivio Spiromax 50 µg - 500 µgTeva
- NetherlandsCortifil 0,5 mg/g crèmeLaboratorios SALVAT, S.A.
- Japanフルチカゾンフランカルボン酸エステルＴ’ｓファーマ
- CzechiaAVAMYSGlaxoSmithKline Trading Services Limited, Dublin
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Flixonase Aquosum, Flixotide Diskus Forte
- Belgium · Flixonase Aqua, Flixotide
- Bulgaria · Аркуист, Фликсоназе
- Cyprus · Cutivate, Flixonase Aqueous
- Czechia · Flixotide Diskus, Flixotide Inhaler N
- Germany · Flutica, Fluticason Cipla
- Denmark · Flixotide, Flurhin
- Estonia · Cutivate Cream, Flixonase
- Spain · Avancort, Flixonase
- Finland · Flixonase, Flixotide Diskus
- United Kingdom (Northern Ireland) · Aeronate, Boots Allergy Relief
- Greece · Alerxem, Bocacort-S
- Croatia · Flixonase, Flixotide Inhaler
- Hungary · Cutivate, Flixonase
- Ireland · Arquist, Flixonase Allergy Relief
- Iceland · Avamys, Flixotide
- Italy · Aktanos, Deflut
- Liechtenstein · Avamys
- Lithuania · Cutivate, Flixotide
- Luxembourg · Flixonase Aqua, Flixotide
- Latvia · Flixonase, Flixotide
- Malta · Cutivate, Flihaler
- Netherlands · Cortifil, Cutivate
- Norway · Avamys, Flurhin
- Poland · Cutivate, Fanipos
- Portugal · Brisovent Diskus, Brisovent Inalador
- Romania · Arquist, Cutivate
- Sweden · Arquist, Fluticasone Cipla
- Slovenia · Flixonase, Flixotide
- Slovakia · Flixonase Aqueous, Flixotide Diskus
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d22746b1-67f2-4fe3-9d6b-cc1ac124e3d4 GET /v1/drugs/d22746b1-67f2-4fe3-9d6b-cc1ac124e3d4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "64103073",
"date_amm": "2024-07-18",
"type_amm": "Procédure décentralisée",
"numero_ue": null,
"substance": "FUROATE DE FLUTICASONE",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "suspension pour pulvérisation",
"voies_administration": "nasale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about furoate de fluticasone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.